VB-CHEP chemotherapy regimen for aggressive non-Hodgkin's lymphomas

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) remains the standard chemotherapy for aggressive non-Hodgkin's lymphoma (NHL).
• There is an ongoing need for improved treatment strategies to enhance patient outcomes in aggressive NHL.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of a novel combination chemotherapy regimen, VB-CHEP, for patients with aggressive NHL.
• To assess the response rates, remission duration, survival, and toxicity profile of the VB-CHEP regimen.

Main Methods:

• A total of 29 patients with aggressive NHL were enrolled in the study.
• Patients received the VB-CHEP regimen, with some undergoing consolidation therapy (cisplatin and cytarabine) or radiotherapy for bulky disease.
• Objective response, complete remission (CR), partial remission (PR), relapse rates, toxicity, and survival were assessed.

Main Results:

• An objective response rate of 82.8% was observed, with a CR rate of 72.4% and a PR rate of 10.3%.
• CR rates were lower in patients with advanced stage, extranodal disease, or bone marrow involvement.
• Median follow-up was 34+ months, with 17 patients disease-free. Median response duration was 29+ months, and median survival was 48+ months. Hematological toxicity, primarily myelosuppression and neutropenia (50.65%), was mostly grades 1-2.

Conclusions:

• The VB-CHEP regimen, particularly with consolidation therapy for high-risk patients, demonstrates significant efficacy in treating advanced-stage aggressive NHL.
• The observed toxicity profile was acceptable, suggesting VB-CHEP as a viable alternative or addition to current treatment standards.